Skip to content

IVIG and treatment of recurrent implantation failure (RIF)

Effect of IVIg on Pregnancy Rate of Paitent with Recurent Implantation Failure with Immunological Causes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016080527520N3
Enrollment
40
Registered
2016-08-24
Start date
2016-08-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Implantation Failure. Complication associated with artificial fertilization, unspecified

Interventions

1 or 2 days before embryo transfer 400 mg per kilogram of IVIG will be administered intravenously..
Treatment - Drugs
1 or 2 days before embryo transfer 400 mg per kilogram of IVIG will be administered intravenously.

Sponsors

Tabriz university of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 41 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients who experienced at least two implantation failure; patients with Azeri origin; Patients who did not have any type of immunotherapy in his medical history. Exclusion criteria: Patients below 18 years and above 41 years; Patients with abnormal karyotype or chromosomal disorders; patients who have bleeding problems; Patients who have chronic disorders such as diabetes; Patients who have HIV, HCV or HBV positive tests; Patients who have a history of asthma and allergies to certain drugs; patients who have uterus anomalies.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Embryo Implantation. Timepoint: 2 month after intervention. Method of measurement: Laboratory tests and ultrasound.

Secondary

MeasureTime frame
Changes in immune cells. Timepoint: 2 month after intervention. Method of measurement: Flow cytometry, ELISA, RT-PCR.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Yousefi

Tabriz University of Medical Sciences

mehdi_yusefi@yahoo.com+98 413364665

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026